Journal: Nature Communications

Article Title: Mitochondrial vulnerability underlies myocarditis from COVID-19 mRNA vaccine

doi: 10.1038/s41467-026-71295-1

Figure Lengend Snippet: a – c LVEF was measured at 0 and 5 days post-administration of mRNA-1273 in Polg +/D257A mice treated with vehicle ( a ; n = 6), testosterone enanthate (TTE) ( b ; n = 5), or bazedoxifene acetate (BZA) ( c ; n = 6). n represents biologically independent mice. All experiments were performed using male mice aged 8–10 weeks. The centre line indicates the median, the box limits indicate IQR (25th-75th percentiles), and the whiskers extend to 1.5 x IQR ( a – c ). Two-tailed, paired Student’s t -test ( a – c ). Source data are provided as a Source Data file.

Article Snippet: Mice were also intraperitoneally treated with 3 mg/kg bazedoxifene acetate (BZA) (MedchemExpress) or 10 mg/kg testosterone enanthate (TTE) (Fujifilm) dissolved in 100 μl of corn oil, and 1 mg/kg GSK'074 (MedchemExpress), 2 mg/kg MitoQ (Selleck) dissolved in 100 μl of 10% methylcellulose (Fujifilm) containing 0.01% tween-80 (Nacalai).

Techniques: Two Tailed Test

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on cell viability. Co-treatment with bazeboxifene and abemaciclib in (A) SUM159, (B) MDA-MB-231 and (C) 4T1 cells exhibited a synergistic effect, and inhibited cell viability more significantly than either drug monotherapy or DMSO. Data are presented as the mean ± standard deviation. **P<0.01, ***P<0.001, ****P<0.0001. CI<1 indicates a synergistic effect, CI>1 indicates an antagonistic effect and CI=1 indicates an additive effect. Ac, abemaciclib; Ac0.25, 0.25 µM Ac; Ac0.5, 0.5 µM Ac; Bz, bazedoxifene; Bz0.5, 0.5 µM Bz; Bz5, 5 µM Bz; CI, combination index; ns, not significant.

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: Standard Deviation

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on IL-6/STAT3 signaling and downstream targets. Western blot analysis of pSTAT3, STAT3, cyclin D1 and GAPDH after treatment with DMSO, bazedoxifene, abemaciclib or bazedoxifene plus abemaciclib in (A) SUM159 and (B) MDA-MB-231 cells. Abemaciclib monotherapy induced pSTAT3 and cyclin D1, while the bazedoxifene plus abemaciclib combination combated this induction. Ac, abemaciclib; Ac1, 1 µM Ac; Bz, bazedoxifene; Bz5, 5 µM Bz; Bz10, 10 µM Bz; p, phosphorylated.

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: Western Blot

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on cell cycle progression. Cell cycle analysis of (A) SUM159 cells, including (B) quantification, and (C) MDA-MB-231 cells, including (D) quantification, after treatment with DMSO, bazedoxifene, abemaciclib or the bazedoxifene plus abemaciclib combination. The strongest G 0 /G 1 blockage was induced by the bazedoxifene plus abemaciclib combination. Ac, abemaciclib; Ac1, 1 µM Ac; Bz, bazedoxifene; Bz5, 5 µM Bz; Bz10, 10 µM Bz.

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: Cell Cycle Assay

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on cell migration. The migration of (A) SUM159, (B) MDA-MB-231 and (C) 4T1 cells was inhibited to a greater extent when cells were treated with bazedoxifene plus abemaciclib compared with either monotherapy or DMSO. Images were captured at a magnification of ×10. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Ac, abemaciclib; Ac1, 1 µM Ac; Ac2, 2 µM Ac; Bz, bazedoxifene; Bz5, 5 µM Bz; Bz10, 10 µM Bz.

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: Migration, Standard Deviation

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on cell invasion. The invasion of (A) SUM159, (B) MDA-MB-231 and (C) 4T1 cells was inhibited to a greater extent when cells were treated with bazedoxifene plus abemaciclib, compared with either monotherapy or DMSO. Images were captured at a magnification of ×10. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Ac, abemaciclib; Ac0.25, 0.25 µM Ac; Ac1, 1 µM Ac; Bz, bazedoxifene; Bz5, 5 µM Bz.

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: Standard Deviation

Journal: Oncology Letters

Article Title: Synergistic effect of bazedoxifene and abemaciclib co‑treatment in triple‑negative breast cancer cells in vitro

doi: 10.3892/ol.2024.14688

Figure Lengend Snippet: Effects of bazedoxifene, abemaciclib and their combination on apoptosis. Apoptosis analysis of (A) MDA-MB-231 cells after treatment with DMSO, bazedoxifene, abemaciclib, or the bazedoxifene plus abemaciclib combination, and (B) its quantification. The greatest induction of apoptosis was achieved by the bazedoxifene plus abemaciclib combination compared with either monotherapy or DMSO treatment. Ac, abemaciclib; Ac1, 1 µM Ac; Bz, bazedoxifene; Bz10, 10 µM Bz; DN, double negative (negative for FITC and PI, indicative of live cells); FITC_positive, only positive for FITC (indicative of cells in early apoptosis); DP, double positive (positive for FITC and PI, indicative of cells in late apoptosis); PI_positive, only positive for PI (indicative of dead cells).

Article Snippet: Bazedoxifene acetate (cat. no. 102233) and abemaciclib mesylate (cat. no. 206973) were purchased from MedKoo Biosciences, Inc.

Techniques: